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Abstract
Acute severe asthma is one of the most common medical emergency situations in childhood, and
physicians caring for acutely ill children are regularly faced with this condition. In this article we
present a summary of the pathophysiology as well as guidelines for the treatment of acute severe
asthma in children. The cornerstones of the management of acute asthma in children are rapid
administration of oxygen, inhalations with bronchodilators and systemic corticosteroids. Inhaled
bronchodilators may include selective b2-agonists, adrenaline and anticholinergics. Additional
treatment in selected cases may involve intravenous administration of theophylline, b2-agonists and
magnesium sulphate. Both non-invasive and invasive ventilation may be options when medical
treatment fails to prevent respiratory failure. It is important that relevant treatment algorithms
exist, applicable to all levels of the treatment chain and reflecting local considerations and
circumstances.
Introduction
Asthma is the most common chronic disease of childhood
in the western countries, and the incidence has continu-
ously been rising during the last decades [1]. In a recently
published study from Norway, the accumulated lifetime
prevalence of asthma in 10 year old children was as high
as 20% [2]. The majority of children with asthma have sta-
ble disease, and only a minority experience exacerbations
needing hospitalisation or emergency room visits. In
older children, recent advances in treatment seem to have
reduced chronic morbidity as well as the number of acute
exacerbations [3,4]. In infants and younger children, this
goal may be more difficult to achieve, given the heteroge-
neity of obstructive lung disease in this age group. Viral
wheeze is a very common clinical scenario in young chil-
dren, and identification and proper treatment of subjects
with potential for development of asthma and future
exacerbations is still an unresolved challenge [5]. Further-
more, in all age groups, failure of adherence to regular
anti-inflammatory treatment schemes may be an impor-
tant reason why acute asthma is still a common cause of
unscheduled hospitalisations in childhood. Therefore,
physicians who care for acutely ill children will regularly
be faced with acute severe asthma.
During recent years several guidelines have been pub-
lished on treatment of stable as well as on exacerbations
of asthma. Few of these guidelines have focused particu-
larly on childhood asthma. The aim of this article is to
review current knowledge of acute severe asthma in child-
hood, with special emphasis on the acute management.
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Methods
We performed a thorough search in PubMed with the fol-
lowing words in different combinations; asthma, chil-
dren, severe, attack, exacerbation, epidemiology,
pathophysiology, guidelines, treatment, management,
oxygen, adrenaline, b2-agonist, anticholinergics, theo-
phylline, steroids, magnesium, helium, CPAP, BiPAP,
ventilation. Included studies and papers were not system-
atically evaluated regarding design and quality. However,
we have emphasised recent guidelines, Cochrane reviews
and other expert reviews.
Clinical definitions
There is no clear definition of an asthma exacerbation [6].
However, in clinical trials it has often been defined as
requirement for hospitalisation, or need for systemic cor-
ticosteroids [7,8]. Status asthmaticus may be defined as
wheezing which does not respond to initial treatment
with inhaled bronchodilators [9,10].
Epidemiology
The majority of asthma exacerbations are mild or moder-
ate and may be treated at home by the parents or by phy-
sicians outside hospitals. However, in parallel to the
increase of asthma prevalence during the recent decades,
the number of children hospitalised for asthma and
wheezing disorders has also increased [3,4,11] Hospitali-
sations for asthma and wheezing disorders are most com-
mon during the first years of life; in our area ranging from
104/10000 children in the age group 1-2 years to 7/10000
in the age group 9-13 years [3], altogether constituting
16% of all emergency admissions in 2003 [12]. The hos-
pitalisation rates for asthma in older children as well as re-
admissions in all age groups seem to have declined during
the last decades [11]. Some recent studies from the last
few years indicate that also the overall admission rates for
asthma and wheezing disorders have began to level off or
even decline in Europe and the USA [8,9,12]. This devel-
opment has been paralleled by an increase in the regular
use of inhaled corticosteroids, suggesting that acute
attacks at least partly may be a preventable complication
in asthmatic children [8,11].
In preschool children, exacerbations of asthma and
wheezing disorders are far more common in boys than in
girls [3,8,12,13]. With increasing age, this pattern is
reversed, and adult females are twice as likely to be hospi-
talised for asthma as adult males [7,8].
In the northern hemisphere there seems to be a seasonal
pattern for asthma exacerbations in school children, with
a steep rise to a peak during the first part of September
from the lowest incidence during the summer months
("the September epidemic") [8]. This is probably due to
an increased exposure to viral infections after school
recommences. Although not so clear, a similar pattern has
been observed also for pre-school children [8].
Even if severe asthma exacerbations are relatively com-
mon, mortality from asthma in children is rare and
declining [8,14,15]. In the UK the mortality rate for chil-
dren 0-14 years is less than one per 100.000 children per
year [14]. In contrast, there has been a vast increase in the
economic costs associated with asthma. However, the
main economic burden of childhood asthma is linked to
indirect costs, long-term follow up and medication, and
not to hospitalisation [1].
Pathophysiology
Asthma is associated with a chronic inflammation of the
airway mucosa, involving a complex interaction between
T-lymphocytes, neutrophils, eosinophils, epithelial cells
and mast cells [9,16,17]. Cytokines and other mediators
such as histamine, leukotrienes and platelet-activating
factor are released from these inflammatory cells, and
complex interactions between cells and mediators lead to
structural and physiological changes and exposed para-
sympatic nerve endings [9,10,16,17]. Airway hyperreac-
tivity is a physiological consequence of these processes,
providing the asthmatic child with airways primed for a
range of triggers that may lead to further airway obstruc-
tion and clinically to asthma exacerbations [9,10,16,17].
The main trigger in the paediatric age group is viral airway
infections, with rhinoviruses being the most common
[18]. In addition, allergens, tobacco smoke, environmen-
tal irritants, exercise, stress and gastroesophageal reflux
may, separately or by concomitant action, initiate a dete-
rioration of the chronic disease and an asthma attack
(acute in chronicum) [8-10,16,18]. In some children,
food allergy may trigger an acute systemic anaphylactic
response, including severe airway obstruction. During an
asthma attack, the chronic inflammation is aggravated by
degranulation of mast cells and release of histamine, leu-
kotrienes and other mediators, inducing mucosal vasodil-
atation and oedema, increased mucous secretion and
smooth muscle contraction, particularly in the medium
sized and small airways [10]. Thereby, the size of the air-
way lumen decreases resulting in increased resistance to
air flow, particularly towards the end of expiration at low
lung volumes. The severe airflow limitation will further
lead to premature airway closure. To compensate, the
patient increases end-expiratory lung volume by increas-
ing functional residual capacity (FRC), resulting in pul-
monary hyperinflation and air trapping [10]. Further,
operational lung volume is shifted away from the range
with the most severe expiratory airflow limitation. Conse-
quently, airflow resistance is reduced while the work of
breathing and the sense of dyspnoea are increased sinceScandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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the inspiratory muscles are put in a mechanically disad-
vantageous position [10,19].
Airway obstruction, hyperinflation and air trapping may
lead to ventilation/perfusion mismatch and hypoxemia
[10]. Hypoxemia and the increased work of breathing
may result in anaerobic muscle work and accumulation of
lactate. The metabolic acidosis may be further aggravated
by dehydration from poor fluid intake. During an asthma
attack, metabolic acidosis may initially be compensated
for by hyperventilation and a respiratory alkalosis, but as
respiratory failure develops, increasing arterial CO2 will
result in a respiratory acidosis and a further decrease in
arterial pH [9,10].
Increased airflow resistance and pulmonary hyperinfla-
tion combined with increased work of breathing and dis-
turbances in the acid/base balance may impair cardiac
function. During a severe asthma attack, the negative
intrapleural pressure will rise, increasing left ventricular
afterload and the risk of pulmonary oedema [20]. Pulmo-
nary vasoconstriction due to hypoxemia, acidosis and
increased lung volume will also increase the right ven-
tricular afterload. Altogether, these changes may result in
decreased cardiac output and decreased alveolar diffu-
sion, further increasing both hypoxemia and acidosis
[10]. Fluid overload caused by overhydration during treat-
ment or fluid retention associated with inappropriate
secretion of antidiuretic hormone, will put the patient fur-
ther at risk of pulmonary oedema [21,22].
The pathophysiology of an asthma attack is influenced by
the age of the patient and the trigger involved. In young
children, viral aetiology with mucosal oedema predomi-
nates, and muscular bronchoconstriction is less impor-
tant. Conversely, in older children, and particularly
during attacks triggered by allergens, acute bronchospasm
is the most important factor. These discrepancies also
influence the clinical course as well as the response to
treatment [23]. Asthma exacerbations mainly involving
inflammatory processes may require time to develop and
to resolve, and symptoms therefore tend to increase and
improve relatively slowly. In these cases, airway narrow-
ing may mainly be due to inflammatory changes, and
there may be an associated down-regulation of β-recep-
tors [24]. Consequently, the response to β2-agonists may
be limited (figure 1). In contrast, allergen induced attacks
may develop very rapidly with bronchoconstriction as the
dominating pathophysiology, thereby also responding
quickly to bronchodilator treatment.
Assessment
Clinical assessment
The most common symptoms in a child with acute
asthma are cough, wheeze, and prolonged expiration.
Objective signs include a prolonged expiratory phase,
recessions, use of accessory respiratory muscles and cya-
nosis. On auscultation, varying degrees of high and low
frequency expiratory sounds may be heard. In severe and
rapid developing attacks the child may even present with
respiratory failure or frank cardiopulmonary arrest.
Different grading systems have been proposed to evaluate
the severity of acute asthma in children [25-27], but no
firm consensus exists. A clinical grading system for bron-
chopulmonary obstruction has been proposed (table 1)
and applied in treatment recommendations in a Nordic
consensus report [25]. It is important to bear in mind that
the extent of wheeze does not necessarily reflect the extent
of bronchopulmonary obstruction, since some degree of
airflow is required to produce a wheeze [28]. Therefore,
decreasing wheeze and breath sounds and a "quiet chest"
in a child with increasing respiratory efforts may signal
imminent respiratory failure. Conversely, increasing
wheeze in a child with severe asthma may indicate
improvement. Development of respiratory failure is clini-
cally best recognised by close observation of the general
condition of the child, the ability to speak or cry, the men-
tal status and level of anxiety, the skin colour and the
movements of the thoracic cage and abdomen during the
respiratory cycle [10]. Inability or unwillingness to lie
down may be an ominous sign in a child with acute severe
asthma.
Children with a special risk for severe or life-threatening
asthma attacks are those with a history of frequent use of
b2-agonists, frequent or recent treatment with oral corti-
costeroids, a previous history of severe asthma and
chronic severity with impaired lung function [8].
Laboratory assessment
A chest x-ray may be relevant in the search for underlying
complications such as pneumonia or air leakages. How-
ever, in moderate asthma attacks a chest x-ray rarely leads
to changes of treatment [29].
Pulse oximetry is a reliable and noninvasive measure of
oxygenation and should be used in all patients to guide
oxygen supplementation. However, oxygen saturation is
not a good parameter of adequate ventilation in children
who receives oxygen treatment. Thorough and repeated
clinical assessments are required to discover imminent
respiratory failure. Blood gas analyses may support the
clinical judgement, as increasing levels of CO2 is an omi-
nous sign. During a moderate asthma attack, a capillary
blood gas analysis may be sufficient, while in patients
admitted to an intensive care unit, arterial blood gas anal-
yses should be routine [25]. Sequential measurements are
important as respiratory alkalosis with hypocarbia is com-
mon during the early phases of an asthma attack, whileScandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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normalisation and a subsequent increase in the pCO2
may be important indicators of clinical deterioration [10].
Management
The cornerstones of acute asthma management in child-
hood are oxygen, inhalation of bronchodilators and sys-
temic corticosteroids. Additional treatment should be
included as required. Acute asthma is often associated
with anxiety, which may further increase dyspnoea and
bronchopulmonary obstruction. Reassurance is therefore
important, both directly but also indirectly through the
parents. The clinical value of painful procedures must be
considered against their possible aggravating effects. Once
established, an indwelling arterial line vastly reduces the
need for subsequent painful procedures.
Oxygen
Oxygen must be considered as a drug in a situation of
acute asthma, reducing hypoxic pulmonary vasoconstric-
tion and interfering with the ventilation-perfusion mis-
match characteristic for severe bronchoconstriction [30].
Oxygen should be delivered to achieve satisfactory oxygen
saturation in obstructive children with suspected or veri-
fied hypoxia. No controlled studies have evaluated which
level of oxygen saturation that is adequate during an acute
asthma attack, but recent guidelines recommend that oxy-
gen saturation in children should be kept above 95% [26].
Oxygen may be delivered by a face mask or by nasal can-
nulae, and the dose should be adjusted by continuous
monitoring by pulse oxymetry. Oxygen at a rate of 6-8
litres per minute should be used to deliver nebulised
Lung function testing in a girl with severe asthma Figure 1
Lung function testing in a girl with severe asthma. Results of lung function testing of a 13 year old girl with a severe 
asthma exacerbation. Spirometry taken during the first day of hospitalisation measured before (blue line) and 15 minutes after 
(red line) inhalation with a nebulised β2-agonist (Salbutamol 1.0 mg/10 kg). Results demonstrate severely decreased lung func-
tion, and further poor reversibility probably due to long standing inflammation and downregulation of β2-receptors.Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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drugs [26]. In severe cases, oxygen should be administered
before other drugs and before assessment is completed
[26].
Fluid
Acute asthma in children is often preceded by periods of
poor fluid intake and vomiting and may therefore be asso-
ciated with dehydration. Dehydration may increase meta-
bolic acidosis, and treatment should be aimed at restoring
normovolemia by oral (preferably) or by intravenous
fluid substitution [10]. Overhydration will increase pul-
monary oedema and must be avoided. The syndrome of
inappropriate antidiuretic hormone (SIADH) has been
described in severe asthma attacks, and careful monitor-
ing of electrolyte and fluid balance is therefore important
[9,10,21,22].
Injection of adrenaline (epinephrine)
Intramuscular injection of adrenaline 10 μg/kg (0.1 ml
per 10 kg body weight of adrenaline 1 mg/ml) may be
given in severe bronchoconstriction during anaphylaxis.
This treatment may also be an initial option in very severe
exacerbations of asthma and in situations where other
treatment options are not available within reasonable
time [9,26].
Inhalations with β2-agonists
There is substantial documentation for the effect of
inhaled  β2-agonists in acute childhood asthma
[10,26,31]. The drug is traditionally nebulised, and dose
recommendations for salbutamol (albuterol) vary
between 0.5-1.5 mg/10 kg bodyweight, mixed in 2-5 ml
NaCl 9 mg/ml [10]. Inhalations should preferably be
given via a face mask, and if necessary delivered with oxy-
gen. During initial therapy, β2-agonists are often given
intermittently, as repeated inhalations every one to three
hours [26]. There is, however, evidence suggesting that
continuous administration of nebulised β2-agonists may
have a better and prolonged bronchodilatory effect com-
pared to intermittent therapy [9,10,31]. A sustained stim-
ulation of β2-receptors is accomplished, and a possible
rebound bronchoconstriction reported during intermit-
tent therapy is prevented [10,31]. A recommended dose
for children is 0.15 mg/kg in 5 ml NaCl 9 mg/ml given
repeatedly by continuous inhalation. This has been
reported to be safe and well tolerated [31]. Recent guide-
lines suggest a practical approach with continuous inhala-
tion of β2-agonist during the first hour(s) of treatment
and thereafter intermittent inhalations on-demand [26].
In cases with a gradually developing inflammation one
should remember the possibility of a poor response to β2-
agonists due to downregulation of β-receptors (figure 1)
[24]. Other types of inhalations such as adrenaline and
ipratropium bromid may be beneficial in such cases (se
below) [31].
One should also keep in mind that β2-agonist may have
stressful effects on the child, and in some cases high doses
may in fact become counter-productive. Therefore, when
the dose intervals are shorter than the half life of the drug,
or if the strategy of continuous administration is
employed, one should carefully consider and monitor the
general condition of the child. An often used rule of
thumb is that β2-agonist should be administered until
development of significant side effects, a strategy requir-
ing close monitoring by skilled personnel.
There are now several studies demonstrating that pressu-
rised metered dose inhalers (pMDI) in combination with
spacers are as good as or even more effective than nebulis-
ers for intermittent administration of β2-agonist in chil-
dren with moderate to severe acute asthma [31-35]. This
may be the obvious choice for treatment of asthma exac-
erbations in children at home, and should be included in
all written treatment plans. It may, however, also be used
Table 1: Symptom score by clinical assessment in children with asthma (modified from K. Aas [25]).
P0. Normal; no signs of bronchopulmonal obstruction
P1. No dyspnoea. Slightly faint respiratory sounds.
P2. No dyspnoea. Moderate rhonchi. Slightly prolonged expiration. The expiration may be audible.
P3. No dyspnoea at rest. Abundant rhonchi. Slight use of auxiliary respiratory muscles. Low grade jugular recessions may be present.
P4. Slight dyspnoea at rest. Abundant rhonchi. Obvious use of auxiliary muscles. Jugular and intercostal recessions. No cyanosis
P5. Severe dyspnoe at rest. Abundant rhonchi. Wheezy expiration audible without stethoscope. Jugular, intercostal and subcostal chest 
recessions. Slight cyanosis may be present.
P6. Alarming obstruction., often both inspiratory and expiratory. Faint respiratory sounds. Chest recessions. Use of auxillary respiratory muscles 
and high respiratory rate. Cyanosis may be present but not mandatory.Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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initially in emergency outpatient settings as well as in pae-
diatric emergency wards [31]. In mild attacks, 2-4 puffs of
salbutamol 0.1 mg/dose may be sufficient (0.2 - 0.4 mg),
whereas in more severe attacks 10 puffs of salbutamol
may be needed [31]. Oxygen cannot be given with a pMDI
and spacer, excluding this method in the most severe
attacks. However, in children without initial oxygen
requirements, β2-agonist administered via a pMDI and
spacer was less likely to provoke hypoxia and tachycardia
compared to the administration via a nebuliser [32,35].
Therefore, pMDI and spacer has been recommended as
the preferred mode of administration for β2-agonist in
paediatric acute asthma [31].
Nebulised adrenaline
In infants and young children with acute asthma and
wheezing, bronchial smooth muscle spasm is not as
prominent as in older children, and mucosal oedema and
secretion may dominate the pathophysiology [36]. There-
fore, inhaled β2-agonists may be less efficient. Nebulised
adrenaline has a rapid but short acting effect on mucosal
oedema and may be of value as initial treatment also in
severely obstructed older children, before administration
of inhaled β2-agonists.
Studies on the effects of nebulised adrenaline in children
of different ages with bronchopulmonary obstruction
reach various conclusions. Some are positive [37-40]
whilst others conclude negatively [41,42]. In Nordic con-
sensus and national protocols, nebulised adrenaline is
recommended in young children (< 2 years) with acute
asthma, followed by β2-agonist [25,36]. The recom-
mended dose is racemic adrenaline 2 mg in children < 6
months of age and 4 mg in older children, inhaled in 3-5
ml NaCl 9 mg/ml [25]. Alternatively, adrenaline (1 mg/
ml) may be inhaled in a dose of 1.5 mg/10 kg bodyweight
(maximum 2 mg) in 2-5 ml NaCl 9 mg/ml [43].
Inhaled anticholinergics
Current guidelines on acute paediatric asthma recom-
mend inhaled ipratropium bromide as add-on therapy to
β2-agonists. This recommendation is based on several
randomised controlled trials demonstrating reduced hos-
pital admission rates and better lung function when β2-
agonists are given in combination with inhaled ipratro-
pium bromide compared to β2-agonists given alone [44-
46]. Especially when symptoms are refractory to initial
treatment with β2-agonist anticholinergics should be con-
sidered [31]. The recommended dose of nebulised iprat-
ropium bromide is (0.125-) 0.25 mg in 2-5 ml NaCl 9 mg/
ml or the drug may be mixed with the β2-agonist/NaCl
solution [27,31,44]. The dose may be repeated every 20
minute for the first hour and every four hour thereafter
[31]. Ipratropium bromide may also be given as pMDI
with a spacer at the dose of 40 μg [27].
Steroids
An increased inflammatory response is a major part of the
pathophysiology of acute asthma, and prompt treatment
with corticosteroids is important. Steroids act on the
pathophysiology in acute asthma in several ways, mainly
by modifying the action of inflammatory cells, downreg-
ulating the release of proinflammatory cytokines and
thereby controlling the airway inflammation
[9,10,16,31]. Guidelines recommend that all children
with moderate to severe asthma should receive systemic
steroids as a part of the initial treatment [25,26]. This
treatment may reduce the need for hospitalisation, reduce
the risk or relapse after the initial treatment and facilitate
earlier discharge from hospital [47]. There is no evidence
to suggest that intravenous steroids are more effective
than oral steroids, both having effect after 3-4 hours
[31,48,49]. The usual recommendation for oral treatment
is prednisolone 1-2 mg/kg or equivalent [31]. One study
has demonstrated that a lower dose may have similar
effect [50], but more studies are needed to confirm this.
Intravenous hydrocortisone of 4 mg/kg or methylpred-
nisolone 0.5 - 1.0 mg/kg every 4-6 hour are alternatives to
oral steroids, but may be reserved for children unable to
receive oral administration due to severity or low age
[10,31].
Systemic steroids may be given repeatedly, depending on
the initial response. Normally a 3-5 days course may be
sufficient, but longer treatment periods may be necessary
[10,26]. A prolonged course of treatment may be particu-
larly necessary if the exacerbation is the result of long-
standing untreated bronchial inflammation.
Prednisolone may be given once daily, and there is no
need for tapering down even after longer treatment peri-
ods [26,51]. Figure 1 demonstrates the spirometry at of a
13 year old girl at admission before and after the inhala-
tion of nebulised salbutamol, and figure 2 the spirometry
from the same girl after a 10 days course of prednisolone
1 mg/kg.
Inhaled corticosteroids are the cornerstone of regular pre-
ventive anti-inflammatory treatment of asthma, aiming at
reducing chronic morbidity and preventing exacerbations
[26]. It has been a widely recommended practise to dou-
ble or triple the dose of inhaled steroids during exacerba-
tions, but the data to support this is missing [31].
However, recent studies have suggested that high doses if
inhaled steroids during the early phase of an asthma exac-
erbation may be beneficial [52,53], but this approach is
not incorporated in current guidelines and more studies
are needed to evaluate this issue [26].
Additional medication
Theophylline. The positive effect from theophylline infu-
sion on acute asthma is well documented, as are theScandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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potential for side effects and severe or even fatal compli-
cations [10,54-57]. In light of the highly efficient inhaled
bronchodilators and systemic corticosteroids, a theophyl-
line infusion therefore has no place in the routine treat-
ment of children with asthma exacerbations [26]. In our
department, theophylline given rectally or as an infusion
was used in 85% of admissions for childhood asthma in
1984/1985, and in 3% in 1999/2000 [3]. However, in one
study, theophylline infusion had some additional effect in
children with near-fatal asthma, already receiving an
aggressive regimen with multiple inhaled bronchodilators
and intravenous corticosteroids [54]. Wheeler et al con-
cluded that theophylline infusion was superior to terbuta-
line as add on treatment in children with status
asthmaticus [56]. Theophylline may therefore be consid-
ered in children with a poor response to other treatment
measures.
Intravenous b2-agonists may also be considered in chil-
dren with severe asthma who do not respond to other
treatments [31,58,59]. Inhaled drugs may have limited
effect in children with nearly complete airway obstruction
and have practical limitations in ventilated patients. Intra-
venous terbutaline has been shown to improve pulmo-
nary function and gas exchange in children with status
asthmaticus [31,59], whereas others have failed to dem-
onstrate efficacy [60]. A suggested dose may be terbutaline
5-10 ug/kg/h [25], but the dose may be titrated higher
[58]. However, one should bear in mind cardiac side
effects such as dysrythmias, tachycardia and hypertension.
Severe hypokalemia induced by β2-agonists may also
aggravate possible dysrythmias [61]. The effect of inhaled
β2-agonists observed in most cases, limit the need for
intravenous administration to very few children [26].
Spirometry taken after a ten days treatment with prednisolone, approximately 1 mg/kg/day Figure 2
Spirometry taken after a ten days treatment with prednisolone, approximately 1 mg/kg/day. Green lines repre-
sent normal values.Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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Magnesium sulphate. The potential benefit of magnesium
sulphate during acute asthma may be via smooth muscle
relaxation secondary to inhibition of calcium uptake. Sev-
eral studies have evaluated inhaled and intravenous
administration of magnesium sulphate in severe child-
hood asthma, but results are diverging [62,63]. A recent
meta-analysis, however, suggested that intravenous mag-
nesium sulphate may be effective in children with severe
acute asthma, whereas more studies are needed to evalu-
ate the effect of inhaled magnesium sulphate [63]. The
recent GINA-guidelines suggest that intravenous magne-
sium may be considered in acute moderate and severe
asthma with incomplete response to initial treatment dur-
ing the first 1-2 hours [26]. It is interesting that this treat-
ment option is listed before intravenous theophylline.
The dose of intravenous magnesium sulphate children
used in studies is 25 - 100 mg/kg given over 20 minutes
[10,63]. Intravenous magnesium sulphate is not studied
in young children and is not included in recent guidelines
for children younger than five years of age [27].
At present there is no evidence to support the use of
helium oxygen therapy or leukotriene modifiers in the
treatment of children with acute asthma [9,26,64,65].
Furthermore, it is important to avoid the use of sedatives
because of the depressant effect on the respiratory efforts
[26]. In severely agitated children one must consider the
possibility of side effects and drug overdoses, particularly
from adrenergic inhalation or from theophylline. In chil-
dren receiving massive treatment with inhaled and/or
intravenous adrenergic and/or anticholinergic drugs and
maybe also intravenous theophylline, one must observe
for cardiac side effects and if suspected, institute adequate
measures.
Non-invasive and invasive ventilation
A detailed presentation of the principles of non-invasive
and invasive ventilation of children with severe bron-
chopulmonary obstruction is beyond the scope of this
review. However, studies during recent years suggest that
bilevel positive airway pressure (BiPAP) in children with
severe asthma may improve symptoms and ventilation
without significant adverse events and reduce the need for
intubation and mechanical ventilation [9,65-68]. This
treatment may therefore be considered in children not
responding properly to initial treatment and with threat-
ening respiratory failure. However, in younger children,
lack of cooperation, stress and agitation may induce pres-
sure leaks and prevent its use. BiPAP is contraindicated in
the patient with altered mental status [65].
Intubation and positive pressure ventilation of an asth-
matic child may increase bronchoconstriction, increase
the risk of airway leakage and has disadvantageous effects
on circulation and cardiac output [10,69]. Therefore, intu-
bation should be avoided unless respiratory failure is
imminent despite adequate institution of all available
treatment measures. Absolute indications for intubation
include severe hypoxia, cardiopulmonary arrest, and
severe deterioration of the mental status of the child. Rel-
ative indications are progress of respiratory failure and/or
increasing CO2 despite adequate utilisation of all availa-
ble treatment measures. However, children should not be
intubated based on blood gas analyses alone [9,10]. The
clinical signs indicating a severe obstruction or a deterio-
rating clinical situation are described previously under the
heading "assessment", and the importance of close obser-
vation of these signs by an experienced staff cannot be
overestimated.
Before intubation, the child should be properly preoxy-
genated. Atropine may be indicated together with a seda-
tive and a rapid muscle relaxant. Ketamine (1-2 mg/kg i.v)
is often recommended due to its bronchodilating effect
[10]. Shortly after intubation, complications such as
hypotension, cardiac arrest, pneumothorax and hypoxia
may develop [10,70]. Hypotension may be caused by
hyperinflation with decreased veneous return to the heart,
aggravated by the vasodilatory effects of medications used
during intubation. Hypotension may be prevented by a
fluid bolus given prior to intubation, or aggressively
treated if occurring [10].
During mechanical ventilation the child should be well
sedated. Ventilator setting should aim at avoiding hyper-
inflation and intrinsic positive end expiratory pressure
(PEEP). Normally the settings will involve a low inspira-
tory to expiratory ratio, a low respiratory rate and low tidal
volumes. Pressure control, pressure support and permis-
sive hypercapnia may prevent air-leakage [10]. Positive
end-expiratory pressure is debated [68,71].
Management plan
Based on the above considerations and recent guidelines,
we suggest a treatment algorithm for acute asthma in chil-
dren, including dose recommendations (Figure 3). The
suggested use of nebulised adrenaline has some support
from the literature, but has not been included in other
guidelines, for instance the GINA.
All institutions caring for children with acute asthma
should provide to their staff a clear in-house treatment
algorithm, taking local considerations and circumstances
into account.
Differential diagnostic considerations
Physicians facing a child with a suspected acute asthma
attack should consider possible alternative diagnoses
[72]. Respiratory distress resembling an acute attack of
asthma can be caused by other pulmonary conditions,Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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Treatment algorithm for children with moderate or severe asthma exacerbations Figure 3
Treatment algorithm for children with moderate or severe asthma exacerbations.
     Initial treatment 
- Oxygen; saturation > 95% 
- Reassurance of children and parents 
- Avoid sedatives and painful procedures 
Moderate or severe episode. 
The general advice is to administer E2-agonist until effect is achieved or until side effects occur (tachycardia). 
The child needs close observation from skilled personnel in this phase 
- Inhaled E2-agonist  
  - Nebulised Salbutamol 1.0 mg/10 kg  (max 5 mg) in 2-5 ml NaCl 9 mg/ml, may be repeated every 20 min first hour, or 
  - Salbutamol continuously for one hour; 1.5 mg/10 kg (max 5mg) in 5 ml NaCl 9 mg/ml given repeatedly 
- Moderate episode; salbutamol MDI with spacer; 0.1 mg/dose, 1 puff/10 kg  – may be repeated every 20  minutes first hour 
- Inhaled adrenaline – particularly in younger children (<2 years) and in severe attacks 
  - Racemic adrenaline 2 – 5 mg in 2-5 ml NaCl 9 mg/ml or 
  - Adrenalin 1 mg/ml: 1 - 2 mg  in 2-5 ml NaCl 9 mg/ml. 
  - repeat every 1-2 hourly
- Inhaled ipratropium bromide – may be considered in older children in addition to a E2-agonist 
  - Nebulised ipratropium bromide 0.25 mg in 2-5 ml NaCl 9 mg/ml  
  - Moderate episode; ipratropium bromide MDI with spacer, 2 puffs (40 Pg) – may be repeated every 20 min first hour 
- Systemic glucocorticosteroids 
  - Oral glucocorticosteroids (prednisolone 1-2 mg /kg or equivalent) or 
  - Intravenous glucocorticosteroids (methylprednisolone 1 mg/kg or hydrocortisone 4 mg/kg) 
  
Very severe or life-threatening episode, anaphylaxis:  
- Consider i.m adrenaline  
(10 Pg/kg; 0.1 ml/10 kg of adrenaline 1 mg/ml)
Initial assessment 
History    – previous medication and asthma history, particularly severe attacks 
Observation   –chest movements, prolonged expiration, recessions, use of accessory muscles, cyanosis, 
general condition, mental status 
Examination  - wheezing or faint respiratory sounds  
Investigations -  oxygen  saturation  (blood gases when appropriate) 
Reassessment after 1-2 hours 
Oxygen requirement, physical observation and examination as above, consider blood gases 
Poor improvement, severe obstruction 
- continue inhalations as above (observe side effects) 
- Consider 
 -  E2-agonist intravenously (terbutaline 5-10 ug/kg/h) 
  - Theophylline intravenously (loading dose 6 mg/kg, maintenance 0.7-0.9 mg/kg/h) 
     Adjust according to plasma theophylline levels 
  - Magnesium sulphate intravenously; 25 – 100 mg/kg given over 20 minutes 
Reassessments at regular intervals 
Oxygen requirement, physical observation and examination as above, blood gases 
Deterioration –impending respiratory failure 
- Decreasing breath sound – “quite chest” 
- Worsening of general signs and mental status,      
  inability to speak or cry 
- arterial pCO2 > 7.5 – 8 kPa 
Consider 
  - BiLevel CPAP 
 -  Mechanical  ventilation 
Improvement, moderate and decreasing obstruction 
- continue inhalations as above, gradually increasing intervals 
- step down other medications 
- oral glucocorticosteroids to be continued for 1-5 daysScandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:40 http://www.sjtrem.com/content/17/1/40
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such as pneumonia or spontaneous pneumothorax, or by
obstruction in central bronchi, such as aspiration of a for-
eign body, or by obstruction in the trachea or larynx, such
as pseudocroup or vocal cord dysfunction. Hyperventila-
tion may mimic as well as complicate an asthma attack,
particularly in older children [72].
Conclusion
Despite recent progress in the treatment of chronic
asthma in childhood, acute exacerbations will continue to
occur. Physicians working within the field of paediatric
emergency medicine will therefore continue to be exposed
to this clinical scenario. The cornerstones of acute asthma
management in childhood are rapid onset of oxygen treat-
ment, inhalation of bronchodilators and systemic corti-
costeroids. It is important that relevant treatment
algorithms exist, applicable to all levels of the treatment
chain and reflecting local considerations and circum-
stances.
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